GSK drug meets main goal in late-stage study to treat relentless itch
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
FierceBiotech9h
GSK scratches itch for phase 3 win, hitting goal in liver disease trial to open up untapped market
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected ...
Business Insider1d
Tharimmune presents clinical data on TH104 for chronic pruritus
Tharimmune (THAR) presented new TH104 clinical data at the American Association for the Study of Liver Disease The Liver Meeting 2024, underway in San Diego from November 15-19. The Phase 1 trial was ...
pharmaphorum5h
GSK drug raises hopes for patients with PBC itch
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
health.wusf.usf.edu6d
Chronic itch is miserable. Scientists are just scratching the surface
Journalist Annie Lowrey has a rare disease that causes a near-constant itch that doesn't respond to most treatments. She ...
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024PARIS, FRANCE, 18 ...
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
PharmiWeb1d
Iqirvo® (elafibranor) data show efficacy and tolerability for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...
Pharmabiz12h
Ipsen announces Bylvay data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Ipsen announces Bylvay data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS: Paris, France Tuesday, November 19, 2024, 11:00 H ...